Silver Book Fact

The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.

Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group. Forecasting Age-Related Macular Degeneration Through the Year 2050. Arch Ophthalmol. 2009; 127(4): 533-40. http://jama.ama-assn.org/content/301/20/2152.extract

Reference

Title
Forecasting Age-Related Macular Degeneration Through the Year 2050
Publication
Arch Ophthalmol
Publication Date
2009
Authors
Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group
Volume & Issue
Volume 127, Issue 4
Pages
533-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Between 2008 and 2009, the number of Americans age 65-74 who reported trouble seeing (even with glasses or contacts) decreased from 14.3% to 10.3%.  The number of Americans age 75…  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient–…  
  • Anti-VEGF Letter Improvement
    An anti-VEGF therapy for DME improved vision by more than 15 letters in approximately 36-51% of participants in a trial.